Sanofi (SNYNF)
| Market Cap | 99.86B -14.5% |
| Revenue (ttm) | 54.60B +4.8% |
| Net Income | 8.71B +19.9% |
| EPS | 7.15 +23.0% |
| Shares Out | n/a |
| PE Ratio | 11.46 |
| Forward PE | 8.48 |
| Dividend | 4.82 (5.77%) |
| Ex-Dividend Date | May 5, 2026 |
| Volume | 100 |
| Open | 88.50 |
| Previous Close | 83.55 |
| Day's Range | 81.29 - 88.50 |
| 52-Week Range | 80.74 - 106.34 |
| Beta | 0.28 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 30, 2026 |
About Sanofi
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for onc... [Read more]
Financial Performance
In 2025, Sanofi's revenue was 46.72 billion, an increase of 5.49% compared to the previous year's 44.29 billion. Earnings were 7.81 billion, an increase of 40.52%.
Financial numbers in EUR Financial StatementsNews
Sanofi: Availability of the aide-mémoire for Q2 2026 results
Availability of the aide-mémoire for Q2 2026 results Paris, France - July 1, 2026. Sanofi announced today the availability of the aide-mémoire for Q2 2026 results on the "Investors" page of sanofi....
Press Release: Availability of the aide-mémoire for Q2 2026 results
Availability of the aide-mémoire for Q2 2026 results Paris, France – July 1, 2026. Sanofi announced today the availability of the aide-mémoire for Q2 2026 results on the "Investors" page of sanofi.com...
Bargain Hunters: These 3 High-Yielding Stocks Recently Hit New 52-Week Lows
When dividend stocks drop in value, investors have the opportunity to secure some higher-than-typical yields. The stocks listed here haven't been doing well this year, but they offer some attractive d...
Sanofi's Nexviazyme Achieves Key Endpoints In Infantile-Onset Pompe Disease Phase 3 Study
(RTTNews) - Sanofi (SNY) announced that Nexviazyme (avalglucosidase alfa) met all primary secondary endpoints in the Baby-COMET Phase 3 trial for infantile-onset Pompe disease. The study showed that t...
Sanofi (SNY) Reports Positive Phase 3 Results for Nexviazyme in Pompe Disease
Sanofi (SNY) Reports Positive Phase 3 Results for Nexviazyme in Pompe Disease
Sanofi's Nexviazyme Meets Main Goal In Phase 3 Baby-COMET Study
PARIS (dpa-AFX) - Sanofi SA (SNY) said on Tuesday that its Phase 3 Baby-COMET study of Nexviazyme met its primary endpoint in treatment-naïve pediatric patients aged six months and younger with in...
Sanofi: Sanofi's Nexviazyme met all primary and secondary endpoints in infantile-onset Pompe disease phase 3 study
Sanofi's Nexviazyme met all primary and secondary endpoints in infantile-onset Pompe disease phase 3 study Nexviazyme met its primary endpoint, participants alive and free of invasive ventilation, ...
Sanofi Faces EU Probe With Fines Possibly Reaching 10%
Sanofi Faces EU Probe With Fines Possibly Reaching 10%
Sanofi (SNY) Faces EU Antitrust Investigation Over Vaccine Marketing Practices
Sanofi (SNY) Faces EU Antitrust Investigation Over Vaccine Marketing Practices
EU Commission opens antitrust probe into Sanofi's flu vaccine campaign
The European Commission opened on Friday an investigation into whether French drug giant Sanofi breached EU competition rules in a flu vaccine marketing campaign.
Is Kymera Therapeutics The Next Big Rival To Regeneron And Sanofi?
Kymera Therapeutics shares catapulted Thursday after the company wrapped enrollment in an eczema study six months ahead of expectations.
Sanofi: Sanofi Foundation opens new chapter centered on future generations
Sanofi Foundation opens new chapter centered on future generations Paris, June 25, 2026. The Sanofi Foundation is opening a new chapter with a strengthened commitment to children and young people, ...
Press Release: Sanofi Foundation opens new chapter centered on future generations
Sanofi Foundation opens new chapter centered on future generations Paris, June 2 5 , 2026 . The Sanofi Foundation is opening a new chapter with a strengthened commitment to children and young people, ...
MacroGenics To Receive $24.5 Mln Milestone Payment From Sanofi For Recent TZIELD Approval
(RTTNews) - MacroGenics, Inc. (MGNX), a clinical-stage biopharmaceutical company, announced that it will receive a $24.5 million regulatory milestone payment from Sanofi following the recently granted...
Sanofi Wins EU Approval For Cenrifki As First Disability-Targeting Therapy For SPMS Without Relapses
(RTTNews) - Sanofi (SNY) announced that the European Commission has approved Cenrifki (tolebrutinib) as the first medicine in the European Union specifically designed to slow disability progression in...
Sanofi Receives Marketing Rights For Wayrilz In Immune Thrombocytopenia From Japan's MHLW
(RTTNews) - Sanofi (SNY) announced that the Ministry of Health, Labour, and Welfare (MHLW) in Japan has granted marketing and manufacturing approval for Wayrilz in the treatment of persistent or chron...
EU Approves Sanofi's Cenrifki For Non-Relapsing Secondary Progressive Multiple Sclerosis
PARIS (dpa-AFX) - Sanofi SA (SNY) on Tuesday said the European Commission has approved Cenrifki for the treatment of secondary progressive multiple sclerosis (SPMS) in adults who have not experien...
Sanofi Multiple Sclerosis Drug Gets EU Approval
The authorization of Cenrifki for the treatment of secondary progressive multiple sclerosis without relapses follows a rejection from U.S. drug regulators.
Sanofi: Sanofi's Wayrilz approved in Japan to treat immune thrombocytopenia
Sanofi's Wayrilz approved in Japan to treat immune thrombocytopenia Wayrilz is a BTK inhibitor that works through multi-immune modulation to help address the underlying causes of immune thrombocyto...
Press Release: Sanofi's Wayrilz approved in Japan to treat immune thrombocytopenia
Sanofi's Wayrilz approved in Japan to treat immune thrombocytopenia Wayrilz is a BTK inhibitor that works through multi-immune modulation to help address the underlying causes of immune thrombocytopen...
Sanofi: Sanofi's Cenrifki (tolebrutinib) approved in the EU as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses
Sanofi's Cenrifki (tolebrutinib) approved in the EU as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses Cenrifki represents a significant advanc...
The Department of Health - Abu Dhabi: DoH and Sanofi Partner to Advance Vaccine Innovation
ABU DHABI, UAE, June 23, 2026 /PRNewswire/ -- The Department of Health - Abu Dhabi (DoH), the regulator of the healthcare sector in Abu Dhabi, and Sanofi, a worldwide biopharma and vaccines leader...
Sanofi (SNY) Drives $24.5M Milestone Payment to MacroGenics
Sanofi (SNY) Drives $24.5M Milestone Payment to MacroGenics
MacroGenics, Inc.: MacroGenics to Receive Milestone Payment from Sanofi for Recent TZIELD Approval
ROCKVILLE, MD, June 22, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the t...